21039 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Enzymes; Proenzymes; Derivatives thereof; Hydrolases (3) acting on peptide bonds (3.4); Serine endopeptidases (3.4.21) Protein C (3.4.21.69)
SEQUENCE OF ACTIVATED PROTEIN C
#2METHODS FOR THE MEASUREMENT OF PROTEIN C AND ACTIVATED PROTEIN C
#3CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS
#4CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS
#5Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#6TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS
#7Stabilised Compositions of Factor VII Polypeptides
#8Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#9Conjugates of biologically active molecules to functionalized polymers
#10Method of targeting exosomes
#11Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#12Treatment of inflammatory skin disorders
#13Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
#14Conjugates of biologically active molecules to functionalized polymers
#15Treatment of abnormal cutaneous scarring
#16MATERIALS AND METHODS FOR TREATING OR PREVENTING GRAFT-VERSUS-HOST-DISEASE
#17Stabilised Compositions of Factor VII Polypeptides
#18Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#19Use of APC analogue for wound healing
#20Extracellular histones as biomarkers for prognosis and molecular targets for therapy
#21Conjugates of biologically active molecules to functionalized polymers
#22TREATMENT OF ABNORMAL CUTANEOUS SCARRING
#23Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors
#24Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#25Stabilised Compositions of Factor VII Polypeptides
#26Compositions and methods for treatment of ocular diseases
#27USE OF APC ANALOGUE FOR WOUND HEALING
#28Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
#29EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY
#30Anti-histone therapy in acute kidney injury
#31Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
#32TREATMENT OF INFLAMMATORY SKIN DISORDERS
#33Markers for sepsis treatment
#34Treatment of abnormal cutaneous scarring
#35Use of APC analogue for wound healing
#36Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#37Anti-histone therapy for vascular necrosis in severe glomerulonephritis
#38METHODS FOR REDUCING FIBROSIS INDUCED BY PERITONEAL DIALYSIS
#39T cell balance gene expression, compositions of matters and methods of use thereof
#40METHODS FOR TREATING AND PREVENTING RADIATION INJURY USING ACTIVATED PROTEIN C POLYPEPTIDES
#41Extracellular histones as biomarkers for prognosis and molecular targets for therapy
#42TREATMENT OF INFLAMMATORY SKIN DISORDERS
#43Conjugates of biologically active molecules to functionalized polymers
#44METHODS AND COMPOSITIONS FOR REDUCING THE INCIDENCE OF POST-SURGICAL ADHESIONS
#45Extracellular histones as biomarkers for prognosis and molecular targets for therapy
#46TREATMENT AND COMPOSITION FOR WOUND HEALING
#47Manufacturing and purification processes of Complex protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins
#48Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#49Treatment and composition for wound healing
#50METHODS AND COMPOSITIONS FOR REDUCING THE INCIDENCE OF POST-SURGICAL ADHESIONS
#51METHODS FOR PREDICTING AND TREATING INFECTION-INDUCED ILLNESSES AND PREDICTING THE SEVERITY OF INFECTION-INDUCED ILLNESSES
#52Method for controlling the amount of gene product, and agent for controlling the amount of gene product
#53METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER
#54Protein C Zymogen and Methods of Use Thereof to Prevent Cancer Metastases
#55METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER
#56Method for treatment of inflammatory disease and disorder
#57Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins
#58Further use of protein kinase N beta
#59COMPOSITIONS AND METHODS FOR TREATING PLASMA PROTEIN DEFICIENCY DISORDERS
#60PROTEIN C RS2069915 AS A RESPONSE PREDICTOR TO SURVIVAL AND ADMINISTRATION OF ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND
#61LOW VISCOSITY COMPOSITIONS COMPRISING A PEGYLATED GLA-DOMAIN CONTAINING PROTEIN
#62Methods and compositions for the treatment and diagnosis of systemic anthrax infection
#63PROTEIN C PATHWAY ASSOCIATED POLYMORPHISMS AS RESPONSE PREDICTORS TO ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND ADMINISTRATION
#64Further Use of Protein Kinase N Beta
#65Airway Administration of Activated Protein C in Inflammatory Conditions Affecting the Respiratory Tract
#66DOSING REGIMEN OF ACTIVATED PROTEIN C AND VARIANTS HAVING REDUCED ANTICOAGULANT ACTIVITY
#67Airway Administration of Site-Inactived FVIIA in Inflammatory Conditions Affecting the Respiratory Tract
#68TREATMENT AND PREVENTION OF ISCHEMIC INJURY USING ACTIVATED PROTEIN C
#69Method for controlling the amount of gene product, and agent for controlling the amount of gene product
#70SERPINE1 POLYMORPHISMS ARE PREDICTIVE OF RESPONSE TO ACTIVATED PROTEIN C ADMINISTRATION AND RISK OF DEATH
#71PROTEIN C FOR USE IN MAINTAINING HEMOSTASIS
#72Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
#73METHODS AND COMPOSITIONS FOR INTRA-ARTICULAR COAGULATION PROTEINS
#74MEDICAMENT FOR IMPROVING PROGNOSTIC SURVIVAL IN THERAPY OF MALIGNANT TUMOR
#75INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF SUBJECT OUTCOME IN CRITICALLY ILL SUBJECTS
#76ACTIVATED PROTEIN C VARIANTS WITH NORMAL CYTOPROTECTIVE ACTIVITY BUT REDUCED ANTICOAGULANT ACTIVITY
#77Proteomic analysis of active multiple sclerosis lesions
#78Stabilised compositions of factor VII polypeptides
#79Extracellular histones as biomarkers for prognosis and molecular targets for therapy
#80Materials and methods for the detection of nitrated fibrinogen
#81Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage
#82Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
#83Treatment for Autoimmune and Inflammatory Conditions
#84Bispecific antibody targeting a complement factor or complement regulatory protein
#85METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER
#86Conjugates of a Polymer and a Protein Linked by an Oxime Group
#87Medicament for Improving Prognostic Survival in Therapy of Malignant Tumor
#88METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER
#89Methods of treating diseases with activated protein C
#90Neuroprotective activity of activated protein c independent of its anticoagulant activity
#91Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
#92Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
#93Stabilised compositions of Factor VII
#94Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
#95Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions
#96Agent for improving life expectancy in therapy of malignant tumor
#97Neurotrophic factor production accelerator
#98Induction of heterozygous FV Leiden carrier status to reduce mortality in sepsis and to prevent organ damage caused by inflammation and/or ischemia-reperfusion injury
#99Nitrated fibrinogen as a marker for coronary artery disease and rapid blood clot formation
#100Implantable system with drug-eluting cells for on-demand local drug delivery
#101Activated protein c formulations
#102Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity